Streetbeat News

Stock Prices

RDY

Dr. Reddy's Laboratories has agreed to make several payments to Coya Therapeutics, including a $7.5M upfront payment, $4.2M upon IND application acceptance, another $4.2M upon first patient dosing in a Phase 2 trial, and up to $40M in development and regulatory milestones. Additionally, Coya is eligible for up to $677.25M in sales-based milestones.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 12:24 pm

OP

OceanPal reported a decrease in Q3 earnings per share (EPS) to $(1.06) from $1.50 year-over-year (YoY), and a decline in time charter revenues to $3.87M from $5.12M YoY.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 12:21 pm

UWMC

UBS analyst Douglas Harter has initiated coverage on UWM Holdings (NYSE:UWMC) with a Sell rating and set a price target of $4.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 12:20 pm

COYA

Coya Therapeutics shares are set to resume trading at 7:35 a.m. ET after a halt.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 12:19 pm

EYEN

RVP

STXS

VRME

Insiders at four companies with stocks under $2—Eyenovia, Retractable Technologies, Stereotaxis, and VerifyMe—have recently made notable purchases of their company's shares. These transactions can signal insider confidence and are often considered by investors when evaluating penny stocks. Stereotaxis and Retractable Technologies reported downbeat results, while VerifyMe and Eyenovia posted positive updates.

Portfolio Pulse from Lisa Levin

December 06, 2023 | 12:16 pm

INMD

InMode Ltd. has revised its 2023 revenue forecast downwards from the previous range of $500M-$510M to a new range of $485M-$495M. Additionally, the company has adjusted its earnings per share (EPS) outlook from $2.53-$2.57 to $2.47-$2.50.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 12:09 pm

INMD

InMode Ltd. has revised its full-year 2023 guidance downward due to a slowdown in platform sales, primarily in North America. This revision reflects challenges in the market that may affect the company's revenue and growth expectations for the year.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 12:07 pm

LOVE

Lovesac (NASDAQ:LOVE) reported Q3 earnings with losses per share of $(0.15), outperforming the consensus estimate of $(0.30) by 50%. Year-over-year, this represents a 68.75% improvement from $(0.48) per share. Quarterly sales reached $154.04M, slightly surpassing the $153.81M estimate and marking a 14.28% increase from the previous year's $134.78M.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 12:03 pm

UNFI

United Natural Foods (UNFI) reported Q1 adjusted EPS of $(0.04), surpassing the $(0.21) estimate, marking an 80.95% beat but a 103.54% decrease from $1.13 per share last year. Sales reached $7.55B, slightly missing the $7.62B estimate by 0.89%, yet representing a 0.27% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 12:01 pm

MDB

Over the last 3 months, 11 Wall Street analysts have provided ratings for MongoDB (NASDAQ:MDB), with an average 12-month price target of $454.55, a slight decrease from the previous target of $465.00. The ratings include 5 bullish, 5 somewhat bullish, and 1 indifferent, with no bearish sentiments. These ratings are used by investors to help guide stock trading decisions and are updated typically once a quarter.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 12:00 pm